Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Ibrigampar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors InteKrin Therapeutics
- 15 Jun 2009 New trial record.
- 10 Jun 2009 The primary endpoint "fasting glucose level" has been met, according to a InteKrin media release.
- 06 Jun 2009 Results presented at the 68th Annual Scientific Sessions of the American Diabetes Association.